VF
KRYS icon

Virtu Financial’s Krystal Biotech KRYS Stock Holding History

Virtu Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,599
Closed -$640K – 1615
2024
Q1 		$640K Buy
+3,599
New +$500K 0.05% 342
2023
Q3 		– Sell
-2,259
Closed -$265K – 1606
2023
Q2 		$265K Buy
+2,259
New +$231K 0.02% 666
2019
Q4 		$328K Buy
+5,920
New +$290K 0.03% 634

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Virtu Financial's KRYS Position: Q2 2024 in Review

Virtu Financial sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 3,599 shares — an estimated $640K sold.

Virtu Financial first reported a position in KRYS in Q4 2019 and held it in 3 quarters. The position peaked at $640K in Q1 2024. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

  • Virtu Financial reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
  • Virtu Financial sold 3,599 Krystal Biotech shares in Q2 2024, an estimated $640K.
  • Virtu Financial first reported a position in Krystal Biotech in Q4 2019 and held it in 3 quarters.
  • Virtu Financial's Krystal Biotech position peaked at $640K in Q1 2024.
  • 245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Virtu Financial's 13F filing for Q2 2024, filed 9 Aug 2024.